Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI
Status:
Completed
Trial end date:
2019-02-19
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to confirm the efficacy of a single oral 900mg dose of
nolasiban to increase the ongoing clinical pregnancy rate at 10 weeks post embryo transfer
(ET) day.